---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-039020"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2026-10-08T11:17:49+00:00"
generated_at: "2026-10-12T15:38:15.551451+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q1 FY27 sales rise 6.9% to $80.9M; adjusted loss narrows to $0.04, FY27 guidance reiterated

## Summary
- Net sales $80.9M, up 6.9% YoY; Med Tech $39.9M (+13.2%) and Med Device $41.0M (+1.4%); GAAP loss per share $0.17 vs $0.26 a year ago.
- Adjusted loss per share $0.04 vs $0.10; adjusted EBITDA $5.0M vs $2.2M; gross margin 59.4% (+410 bps), or 57.8% excluding tariff refunds; $34.0M cash, debt-free.
- Auryon sales $18.9M (+14.7%), NanoKnife $8.3M (+29.0%), AlphaVac +37.4%, AngioVac -5.9%; Mechanical Thrombectomy $12.0M (+6.7%).
- FY27 guidance reiterated: net sales $336-341M, Med Tech growth 12-15%, Med Device flat, gross margin 54-55%, adjusted EBITDA $13-16M, adjusted EPS -$0.29 to -$0.24.
- Eric Honroth named President and CEO effective Nov 2, 2026, succeeding retiring Jim Clemmer; FDA IDE approved for RELIEF, a 40-patient NanoKnife IRE study in BPH.

## SEC filing metadata
- accession: 0001140361-26-039020
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2026-10-08T11:17:49+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036126039020/0001140361-26-039020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036126039020/ef20083493_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-039020
- JSON: https://secwatch.observer/filing/0001140361-26-039020.json
- Plain text: https://secwatch.observer/filing/0001140361-26-039020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.